ARTICLE | Strategy

Cephalon Blasts into CV

Cephalon enters cardiovascular space with Mesoblast stem cell deal

December 13, 2010 8:00 AM UTC

Cephalon Inc. continued its expansion into specialty disease areas last week via a partnership with Mesoblast Ltd. that marks Cephalon's first foray into the cardiovascular space.

Cephalon received worldwide rights to Mesoblast's adult Mesenchymal Precursor Stem Cell (MPC) technology in three treatment areas: neurodegenerative disease; augmenting hematopoietic stem cell transplantation in cancer patients; and cardiovascular disease...